Patents by Inventor Scott A. Reines

Scott A. Reines has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating or preventing depression
    Publication number: 20030022814
    Abstract: A neurokinin-1 antagonist or an alpha-2 adrenoreceptor agonist provide an effective therapy in conjunction with a PDE4 inhibitor for the treatment or prevention of depression and/or anxiety. These combinations minimize the side effects of nausea and/or emesis associated with the PDE4 inhibitor and may also provide beneficial antidepressant and/or anti-anxiety effects.
    Type: Application
    Filed: August 23, 2002
    Publication date: January 30, 2003
    Inventors: Scott A Reines, Annette Robichaud, Frederick D Tattersall
  • Method of treating migraines and pharmaceutical compositions
    Publication number: 20020177617
    Abstract: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.
    Type: Application
    Filed: March 26, 2002
    Publication date: November 28, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Kremena Simitchieva, Scott A. Reines, Errol McKinney, Eric J. Sandquist, Deepak K. Khannna, Richard Hargreaves
  • Method of treating migraines and pharmaceutical compositions
    Patent number: 6384034
    Abstract: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Kremena Simitchieva, Scott A. Reines, Errol McKinney, Eric J. Sandquiest, Deepak K. Khannna, Richard Hargreaves
  • Method of treating migraines and pharmaceutical compositions
    Publication number: 20020016348
    Abstract: A combination of a 5HT1B/1D agonist and a COX-2 selective inhibitor is useful in the treatment and or prevention of migraine.
    Type: Application
    Filed: August 22, 2001
    Publication date: February 7, 2002
    Applicant: Merck & Co. Inc.
    Inventors: Kremena Simitchieva, Scott A. Reines, Errol Mckinney, Eric J. Sandquist, Deepak K. Khannna, Richard Hargreaves
  • Method for treating or preventing depression
    Publication number: 20010049368
    Abstract: A neurokinin-1 antagonist or an alpha-2 adrenoreceptor agonist provide an effective therapy in conjunction with a PDE4 inhibitor for the treatment or prevention of depression and/or anxiety. These combinations minimize the side effects of nausea and/or emesis associated with the PDE4 inhibitor and may also provide beneficial antidepressant and/or anti-anxiety effects.
    Type: Application
    Filed: February 27, 2001
    Publication date: December 6, 2001
    Inventors: Scott A. Reines, Annette Robichaud, Frederick D. Tattersall
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4983400
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: January 8, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4900755
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.
    Type: Grant
    Filed: February 24, 1989
    Date of Patent: February 13, 1990
    Assignee: Merck & Co.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines
  • Controlled release combination of carbidopa/levodopa
    Patent number: 4832957
    Abstract: A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
    Type: Grant
    Filed: July 25, 1988
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Dempski, Edward C. Scholtz, Donald W. Nibbelink, Scott A. Reines